N/A
N=50
Physical Therapy Treatment Once a Month Versus Once a Week for Posture Improvement in Children and Adolescents
Postural Kyphosis, Thoracic Region
Bottom Line
View on ClinicalTrials.gov: NCT03046472 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Jan 2020
Primary outcome: Primary: Thoracic Kyphosis Angle — 39.2; 38.9; 27.9; 28.2 degrees — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Physical Therapy treatment for Postural Behavior (Other)
- Age
- Pediatric, Adult · 10+ yrs
- Sex
- All
- Sponsor
- Assuta Hospital Systems
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Thoracic Kyphosis Angle |
39.2; 38.9; 27.9; 28.2 | <0.001 sig |
| PRIMARY Low Back Pain |
5.5; 5.6; 2.8; 1.6 | <0.001 sig |
| PRIMARY Back Postural Behavior |
6.7; 9.0; 3.0; 4.1 | 0.01 sig |
Summary
This study is design in a clinical setting for testing whether physical therapy treatment that includes postural awareness exercises for strength flexibility and endurance is improving low back pain and postural behavior. The study will consist of two groups, basic treatment that will get one on one treatment once a month for 3 months and the intervention group, will get an additional group therapy once a week.
Eligibility Criteria
Inclusion Criteria
- Children and Adolescent who referred by their pediatrician or orthopedic doctor to Physical Therapy treatment due to bad posture or Low Back Pain
- At the Physical Therapy clinic was found that this is truly the condition of bad posture or low back pain with bad posture.
- age 10-18 years
- they signed on informed consent.
Exclusion Criteria
- Children and Adolescent who suffer from risk of structural deterioration as structural scoliosis(Cob angle above 20° and Risser sign equal or below 3) or structural Kyphosis (above 40° Risser sign equal or below 3 or Scheuermann Disease)
- Any sever health condition neurologic internal or orthopedic like Cerebral Palsy, Juvenile rheumatoid arthritis or Malignancy.
Data sourced from ClinicalTrials.gov (NCT03046472). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.